NHS National Technology Adopt

RNS Number : 6642B

Deltex Medical Group PLC

20 August 2008

 



Deltex Medical Group plc

NHS National Technology Adoption Hub sales update

20 August 2008 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the UK's leading haemodynamic monitoring company, announced in October 2007 that its CardioQ-ODM™ system was one of the first products to be selected under the NHS National Technology Adoption Hub ('NTAH') programme. The Manchester Royal Infirmary ('MRI') is one of the three hospitals enrolled in the NATH programme and Deltex Medical today announces that MRI has purchased four CardioQ-ODM monitors to enable it to participate in the NTAH project.

The NTAH has been established as a key element of the NHS innovation agenda which is aimed at ensuring that NHS patients in England benefit earlier from proven new medical technologies. The NTAH website is  www.technologyadoptionhub.nhs.uk.

The MRI is one of the UK's largest teaching hospitals and is part of the Central Manchester and Manchester Children's University Hospitals NHS Trust. It is the largest of three hospitals participating in the first phase of the NTAH project. The four CardioQ-ODM monitors have been acquired for use in its operating theatres. The Company plans to begin a clinician training programme on 28 August and expects the MRI to start ordering CardioQ-ODM probes by the end of the first week in September.

The other two hospitals participating in the first phase of the NTAH project are the Whittington Hospital in London and Derby Hospital in the East Midlands. Clinical implementation started at the Whittington Hospital in July while the Company began its clinician training programme at Derby Hospital in early August.

Deltex Medical's Chief Executive, Andy Hill commented:

'We believe that the order from the Manchester Royal Infirmary means that the NHS National Technology Adoption Hub's project on our products will shortly be up and running at all three participating sites.'

For further information, please contact:-

Deltex Medical Group plc                                                     01243 774 837

Nigel Keen, Chairman                                                             [e-mail]

Andy Hill, Chief Executive                                                       [e-mail]

Ewan Phillips, Finance Director                                               [e-mail] 

Gavin Anderson & Company                                                 0207 554 1400

Deborah Walter                                                                      [e-mail]

Robert Speed                                                                         [e-mail]

Stuart Macaulay                                                                     [e-mail] 

Nominated Adviser & Broker

Charles Stanley Securities                                                   020 7149 6000

Philip Davies                                                                          [e-mail] 

Russell Cook                                                                         [e-mail] 

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 100 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRAGGGMRKLRGRZM